drugset / Trial / NCT02260089

Telmisartan in Mild to Moderate Hypertensive Patients

NCT02260089

Phase 4 Completed 134 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and tolerability of telmisartan, given once a day to patients with mild to moderate hypertension, as well as to assess the 24-hour blood pressure profile with ABPM

Timeline

Start
2000-03
Primary completion
2002-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Telmisartan Other / unclassified

Indications